A short suppression regimen with daily 0.5 mg leuprolide commencing the first day of in vitro fertilization (IVF) cycles was evaluated in 10 women who previously underwent similar IVF cycle without suppression. Induction of ovulation, oocyte retrieval, incubation, and embryo transfer were similar in all the cycles. Assessment included the amount of human menopausal gonadotrpin (hMG) used, length of stimulation, serum estradiol and luteinizing hormone (LH) levels, number of oocytes retrieved and their quality, cleavage rate, and number of embryos. The results showed that when leuprolide was used, no endogenous LH surge was detected, and there was a significant increase in hMG injected, from 19.0±5.8 to 34.4±17 ampoules, and in estradiol, levels, from 1276±470 to 2618±1084 pg/ml (mean ± SD). In addition, there was an increase in the total oocytes retrieved from 54 to 94, their cleavage rate from 59 to 86%, and the number of embryos from 24 to 70 in the suppressed cycle. No deleterious effects were observed and there were two pregnancies in this group.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Kerin JF, Warnes GM: Monitoring of ovarian response to stimulation in in vitro fertilization cycles. Clin Obstet Gynecol 1986; 29:158
Messinis IE, Templeton A, Baird DT: Endogenous luteinizing hormone surge during superovulation induction with sequential use of clomiphene citrate and pulsatile human menopausal gonadotropin. J Clin Endocrinol Metab 1985; 61:1076
Vargyas JM, Morente, C, Shangold G, Marrs RP: The effect of different methods of ovarian stimulation for human in vitro fertilization and embryo replacement. Fertil Steril 1984; 42:745
Casper RF, Erskine HJ, Armstrong DT, Brown SE, Daniel SA, Graves GR, Yuzpe AA: In vitro fertilization: Diurnal and seasonal variation in luteinizing hormone surge onset and pregnancy rates. Fertil Steril 1988; 49:644
Lejeune B, Degueldre M Camus M, Vekemans M Opsomer L, Leroy F: In vitro fertilization and embryo transfer as related to endogenous luteinizing hormone rise or human chorionic gonadatropin administration. Fertil Steril 1986; 45:377
Ferraretti AP, Garcia JE, Acosta AA, Jones GS: Serum luteinizing hormone during ovulation induction with human menopausal gonadotropin for in vitro fertilization in normally menstruating women. Fertil Steril 1983; 40:742
Keningsberg D, Littman BA, Williams RF, Hodgen GV: Medical hypophysectomy. II. Variability of ovarian response to gonadotropin therapy. Fertil Steril 1984; 42:116
Neveu S, Hedon B, Bringer J, Chinchole JM, Arnal F, Humeau C, Cristol P, Viala JL: Ovarian stimulating by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril 1987; 47:639
Laufer N, DeCherney AH, Haseltine FD Polan ML, Mezer HC, Dlugi AM, Sweeney D, Nero F, Noftolin F: The use of high-dose human menopausal gonadotropin in an in vitro fertilization program. Fertil Steril 1983; 40:734
Radwanska E, Rawlins RG, Tummon I, Maclin V, Binor Z, Dmowski WP: Successful use of gonadotropin-releasing hormone agonist leuprolide for in vitro fertilization in a patient with polycystic ovarian disease and infertility unresponsive to standard treatment. Fertil Steril 1988; 49:356
Barriere P, Lopes P, Boiffard JP, Pousset C, Quentin M, Sagot P, Hermite AL, Lerat MF, Charbonnel B: Use of GnRH analogues in ovulation induction for in vitro fertilization: Benefit of a short administration regimen. J Vitro Fert Embryo Transfer 1987; 4:64
Barnes R, Scommegna A, Schreiber J: Decreased ovarian response to human menopausal gonadotropin, caused by subcutaneously administered gonadotropin-releasing hormone agonist. Fertil Steril 1987; 47:512
Culter GB Jr, Hoffman A, Swerdloff RS Santen RJ, Meldrum DR, Comite F: Therapeutic applications of luteinizing-hormone-releasing hormone and its analogs. Ann Intern Med 1985; 102:643
Sopelak VM, Whitworth NS, Cowan BD: Combination lowdose gnRH agonist/human menopausal gonadotropin treatment of women with previously cancelled in vitro fertilization (IVF) cycles. Society for Gynecologic Investigation, 35th Annual Meeting, March 17–20, 1988 Abstr 145
Tureck R, Mastroianni L Jr, Blasco L, Strauss JF III: Inhibition of human granulosa cell progesterone secretion by a gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 1982; 54:1078
Serafini P, Stone B, Kerin J, Batzofin J, Quinn P, Marrs RP: An alternate approach to controlled ovarian hyperstimulation in “poor responders”: Pretreatment with a gonadotropin-releasing hormone analog. Fertil Steril 1988; 49:90
Dodson W, Myers T, Morton P, Conn P: Leuprolide acetate: Serum and follicular fluid concentrations and effects on human fertilization, embryo growth, and granulosa-lutein cell progesterone accumulation in vitro. Fertil Steril 1988; 50:612
Frydman R, Allart J, Parneix I, Forman R, Hazout A, Testart J: Comparison between flare up and down regulation effects of luteinizing hormone-releasing hormone agonists in an in vitro fertilization program. Fertil Steril 1988; 50:471
Quigley M, Sokoloski J, Richards S: Timing human chorionic gonadotropin administration by days of estradiol rise. Fertil Steril 1985; 44:791
About this article
Cite this article
Henig, I., Chan, P.J., Prough, S.G. et al. Effectiveness of short pituitary suppression with gonadotropin-releasing hormone agonist leuprolide during induction of ovulation for in vitro fertilization. J Assist Reprod Genet 6, 195–200 (1989). https://doi.org/10.1007/BF01132864
- in vitro fertilization